JUN 1 4 2004 &

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE guired to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

Under the Paperwork Reduction Act of 19

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of |2

 Complete if Known

 Application Number
 10/734,917

 Filing Date
 12/12/2003

 First Named Inventor
 David J. Dooley

 Art Unit
 1621

 Examiner Name
 Unknown

 Attorney Docket Number
 PC25870A

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Y		<sup>US-</sup> 4,024,175	05-17-1977	G. Satzinger, et al.	
		<sup>US-</sup> 4,087,544	05-02-1978	G. Satzinger, et al.	
N		US- 6,306,910	10-23-2001	L. Magnus, et al.	
		US-			
****		US-			
		US-			
		US-			
		U\$-			
		US-			-
		U\$-			
		U\$-			<del></del>
		US-			
		US-			
		US-	<del> </del>		

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines,	Τ
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# known)	MM-DD-YYYY	Typinamic or Oned December	Where Relevant Passages Or Relevant Figures Appear	
QC'	EP	0641330 B1	10-17-2001	R. B. Silverman, et al.		
	wo	98/17627 A1	04-30-1998	J. S. Bryans, et al.		
	WO	99/21824 A1		J. S. Bryans, et al.		Г
	wo	00/76958 A2	12-21-2000	T. R. Belliotti, et al.		
	wo	01/28978 A1		J. S. Bryans, et al.		
A	wo	01/90052 A1		J. S. Bryans, et al.	· · · · · · · · · · · · · · · · · · ·	

Examiner	(1)	Date
Signature	('6')	Considered (0)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Transation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Please type a plus sign (+) inside this box ->	$\Box$	I

PTO/SB/08B (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
	0011.	D.	01 00115-	Application Number	10/734,917		
INF	ORMAII	on dis	CLOSURE	Filing Date	December 12, 2003		
STATEMENT BY APPLICANT				First Named Inventor	David J. Dooley		
				Group Art Unit	1621		
(use as many sheets as necessary)				Examiner Name	Unknown		
Sheet	2	of	2	Attorney Docket Number	PC25870A		

	l	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	Т
Examiner Ci Initials' No		item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
x		M. V. AMERINGEN et al., "Drugs in development for social anxiety disorder:more to social anxiety than meets the SSRI" Expert Opinion on Investigational Drugs, Ashley Pub. Ltd., London, GB 2000:2215-2231; Vol.9, No. 10	
		A. BARKHUIZEN, "Rational and targeted pharmacologic treatment of fibromyalgia" Rheum Dis Clin N Am 2002;28:261-290	
		R. M. BENNETT, "The rational management of fibromyalgia patients" Rheum Dis Clin N Am 2002; 28: 181-199	
		D. BUSKILA, "Fibromyalgia, chronic fatigue syndrome and myofacial pain syndrome" Current opinions in Rheumatology 2001;13:117-127	
		B. L. EHRENBERG, et al., "Open-Label Trial of Gabapentin for Periodic Limb Movement Disorder of Sleep", 1997, pp A278-A279, Vol. 48	
		E. K. GUYMER, et al., "An approach to managing fibromyalgia" Medicine Today 2002:58-59; Vol. 3, No. 12	
		L. J. LEVENTHAL, "Management of fibromyalgia" Ann Intern Med 1999;131:850-8	
		L. T. MELTZER, et al., "Pregabalin enhances non-rapid eye movement sleep and eeg slow-wave activity in rats" Society for neuro. abstracts 2001:2245 Vol. 27, No. 2	
		I. SELAK, "Pregabalin (Pfizer)" Current opinion in investigational drugs, current drugs, Lond, GB 2001:828-834; Vol. 2, No. 6	
		F. WOLFE, et al., "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee" Arthritis Rheum 1990; 33:160-72	
\$		M. B. YUNUS. "A comprehensive medical evaluation of patients with fibromyalgia syndrome" Rheum Dis N Am 2002; 28:201-217	-

Examiner A A 1	Date	104
Signature ( ( )	Considered	11121
799	00113146164	1 (4)

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.





<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please	type a	plus sign	(+) ins	ide this	box	<b>→</b>	+	
--------	--------	-----------	---------	----------	-----	----------	---	--

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO SUPPLEMENTAL

Examiner

Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/734,917 December 12, 2003 Filing Date David J. Dooley First Named Inventor 1621 Group Art Unit Unknown **Examiner Name** Attorney Docket Number PC25870A

(use as many sheets as necessary) Sheet of

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials' publisher, city and/or country where published. D. Garcia-Borreguero et al., "Treatment of restless legs syndrome with gabapentin--A double-blind, cross-over study" Neurology 2002;59:1573-1579 S

Date

Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.